Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels

Wadman M, Couzin-Frankel J, Kaiser J, Matacic C (2020) A rampage through the body. Science 368(6489):356–360 Puelles VG, Lutgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S et al (2020) Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 383(6):590–592 Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M (2020) Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 92(7):699–702 Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brunink S, Greuel S et al (2021) Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 24(2):168–175 Iadecola C, Anrather J, Kamel H (2020) Effects of COVID-19 on the nervous system. Cell 183(1):16-27 e11 Doyle MF (2021) Central nervous system outcomes of COVID-19. Transl Res. https://doi.org/10.1016/j.trsl.2021.09.002 https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS et al (2021) Post-acute COVID-19 syndrome. Nat Med 27(4):601–615 Xie Y, Bowe B, Al-Aly Z (2021) Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun 12(1):6571 Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ (2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8(5):416–427 Achar A, Ghosh C (2020) COVID-19-associated neurological disorders: the potential route of CNS invasion and blood-brain relevance. Cells 9(11):2360 Erickson MA, Rhea EM, Knopp RC, Banks WA (2021) Interactions of SARS-CoV-2 with the blood-brain barrier. Int J Mol Sci 22(5):2681 Frank MG, Nguyen KH, Ball JB, Hopkins S, Kelley T, Baratta MV, Fleshner M, Maier SF (2022) SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties. Brain Behav Immun 100:267–277 Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, Holden SJ, Raber J, Banks WA, Erickson MA (2021) The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci 24(3):368–378 Iroegbu JD, Ifenatuoha CW, Ijomone OM (2020) Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. Neurol Sci 41(6):1329–1337 Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22 Cardinali DP (2019) Melatonin: clinical perspectives in neurodegeneration. Front Endocrinol (Lausanne) 10:480 Liu L, Labani N, Cecon E, Jockers R (2019) Melatonin target proteins: too many or not enough? Front Endocrinol (Lausanne) 10:791 Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP (2016) Update on melatonin receptors. IUPHAR review. Br J Pharmacol 173(18):2702–2725 Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML (2016) MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol 56:361–383 de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9(8):628–642 Schrire ZM, Phillips CL, Chapman JL, Duffy SL, Wong G, D'Rozario AL, Comas M, Raisin I, Saini B, Gordon CJ et al (2021) Safety of higher doses of melatonin in adults: a systematic review and meta-analysis. J Pineal Res e12782 Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farres J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J et al (2020) In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS ONE 15(10):e0240149 Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 6:14 Romero A, Ramos E, Lopez-Munoz F, Gil-Martin E, Escames G, Reiter RJ (2020) Coronavirus disease 2019 (COVID-19) and its neuroinvasive capacity: is it time for melatonin? Cell Mol Neurobiol Cardinali DP, Brown GM, Pandi-Perumal SR (2020) Can melatonin be a potential “silver bullet” in treating COVID-19 patients? Diseases 8(4):44 Reynolds JL, Dubocovich ML (2021) Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19. J Pineal Res 71:e12732 Gholizadeh M, Abaj F, Hasani H, Mirzababaei A, Mirzaei K (2021) Does the melatonin supplementation decrease the severity of the outcomes in COVID-19 patients? A mini review of observational data in the in vivo and in vitro studies. Melatonin Res 4(2):348–359 Cecon E, Izabelle C, Poder SL, Real F, Zhu A, Tu L, Ghigna MR, Klonjkowski B, Bomsel M, Jockers R et al (2022) Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2. J Pineal Res 72(1):e12772 Golden JW, Cline CR, Zeng X, Garrison AR, Carey BD, Mucker EM, White LE, Shamblin JD, Brocato RL, Liu J et al (2020) Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight. https://doi.org/10.1172/jci.insight.142032 Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allue-Guardia A, Olmo-Fontanez A, Gautam S, Garcia-Vilanova A, Ye C et al (2020) Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun 11(1):6122 Andersen LP, Werner MU, Rosenkilde MM, Harpsoe NG, Fuglsang H, Rosenberg J, Gogenur I (2016) Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol 17:8 Wenzel J, Lampe J, Muller-Fielitz H, Schuster R, Zille M, Muller K, Krohn M, Korbelin J, Zhang L, Ozorhan U et al (2021) The SARS-CoV-2 main protease M(pro) causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci 24(11):1522–1533 Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA, Mann BJ (2020) Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. Am J Trop Med Hyg 103(3):1215–1219 Ramos E, Lopez-Munoz F, Gil-Martin E, Egea J, Alvarez-Merz I, Painuli S, Semwal P, Martins N, Hernandez-Guijo JM, Romero A (2021) The coronavirus disease 2019 (COVID-19): key emphasis on melatonin safety and therapeutic efficacy. Antioxidants (Basel) 10(7):1152 Wu J, Chen ZJ (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 32:461–488 Gilad E, Wong HR, Zingarelli B, Virag L, O’Connor M, Salzman AL, Szabo C (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 12(9):685–693 Tamura EK, Cecon E, Monteiro AW, Silva CL, Markus RP (2009) Melatonin inhibits LPS-induced NO production in rat endothelial cells. J Pineal Res 46(3):268–274 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583(7816):459–468 Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M et al (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370(6518):856–860 Davies J, Randeva HS, Chatha K, Hall M, Spandidos DA, Karteris E, Kyrou I (2020) Neuropilin1 as a new potential SARSCoV2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID19. Mol Med Rep 22(5):4221–4226 Cecon E, Ivanova A, Luka M, Gbahou F, Friederich A, Guillaume JL, Keller P, Knoch K, Ahmad R, Delagrange P et al (2019) Detection of recombinant and endogenous mouse melatonin receptors by monoclonal antibodies targeting the C-terminal domain. J Pineal Res 66(2):e12540 Cecon E, Burridge M, Cao L, Carter L, Ravichandran R, Dam J, Jockers R (2021) SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem Biol 29:74–83 Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B (2009) HTRF: a technology tailored for drug discovery—a review of theoretical aspects and recent applications. Curr Chem Genomics 3:22–32 Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F (2020) Structural basis of receptor recognition by SARS-CoV-2. Nature 581(7807):221–224 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367(6485):1444–1448 Acuna-Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuna-Fernandez C (2020) Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res 69(3):e12683 Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J (2010) International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62(3):343–380 Zulli A, Burrell LM, Buxton BF, Hare DL (2008) ACE2 and AT4R are present in diseased human blood vessels. Eur J Histochem 52(1):39–44 Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13 Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V et al (2021) Microvascular injury in the brains of patients with COVID-19. N Engl J Med 384(5):481–483 Savaskan E, Olivieri G, Brydon L, Jockers R, Krauchi K, Wirz JA, Muller SF (2001) Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer’s disease. Neurosci Lett 308(1):9–12 Lotufo CM, Lopes C, Dubocovich ML, Farsky SH, Markus RP (2001) Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol 430(2–3):351–357 Lotufo CM, Yamashita CE, Farsky SH, Markus RP (2006) Melatonin effect on endothelial cells reduces vascular permeability increase induced by leukotriene B4. Eur J Pharmacol 534(1–3):258–263 Geary GG, Duckles SP, Krause DN (1998) Effect of melatonin in the rat tail artery: role of K+ channels and endothelial factors. Br J Pharmacol 123(8):1533–1540 Hui KPY, Cheung MC, Perera R, Ng KC, Bui CHT, Ho JCW, Ng MMT, Kuok DIT, Shih KC, Tsao SW et al (2020) Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med 8(7):687–695 Robinot R, Hubert M, de Melo GD, Lazarini F, Bruel T, Smith N, Levallois S, Larrous F, Fernandes J, Gellenoncourt S et al (2021) SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance. Nat Commun 12(1):4354 Ortiz ME, Thurman A, Pezzulo AA, Leidinger MR, Klesney-Tait JA, Karp PH, Tan P, Wohlford-Lenane C, McCray PB Jr, Meyerholz DK (2020) Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract. EBioMedicine 60:102976 Li MY, Li L, Zhang Y, Wang XS (2020) Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9(1):45 Tamura EK, Fernandes PA, Marcola M, da Silveira C-M, Markus RP (2010) Long-lasting priming of endothelial cells by plasma melatonin levels. PLoS ONE 5(11):e13958 Hattori SI, Higshi-Kuwata N, Raghavaiah J, Das D, Bulut H, Davis DA, Takamatsu Y, Matsuda K, Takamune N, Kishimoto N et al (2020) GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection. MBio. https://doi.org/10.1128/mBio.01833-20 Zhai X, Wang N, Jiao H, Zhang J, Li C, Ren W, Reiter RJ, Su S (2021) Melatonin and other indoles show antiviral activities against swine coronaviruses in vitro at pharmacological concentrations. J Pineal Res 71(2):e12754 Zhou Y, Hou Y, Shen J, Mehra R, Kallianpur A, Culver DA, Gack MU, Farha S, Zein J, Comhair S et al (2020) A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol 18(11):e3000970 Mousavi SA, Heydari K, Mehravaran H, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Shamshirian A (2022) Melatonin effects on sleep quality and outcomes of COVID-19 patients: an open-label, randomized, controlled trial. J Med Virol 94(1):263–271 Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, Saeedi-Boroujeni A, Rezaie E, Ghaleh HEG, Aghamollaei H, Fasihi-Ramandi M et al (2021) Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: a randomized double-blind clinical trial. Arch Med Res 53:79–85 Hasan ZT, Atrakji D, Mehuaiden DAK (2021) The Effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2021.10.012 Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida A et al (2021) Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. https://doi.org/10.1016/S2214-109X(21)00448-4 Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659–661 Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27–31 Jacob S, Poeggeler B, Weishaupt JH, Siren AL, Hardeland R, Bahr M, Ehrenreich H (2002) Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 33(3):186–187 Nordlund JJ, Lerner AB (1977) The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab 45(4):768–774 Karim A, Tolbert D, Cao C (2006) Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 46(2):140–148 Johnson MW, Suess PE, Griffiths RR (2006) Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 63(10):1149–1157 Loo H, Dalery J, Macher JP, Payen A (2003) Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale 29(2):165–171 Eser D, Baghai TC, Moller HJ (2010) Agomelatine: the evidence for its place in the treatment of depression. Core Evid 4:171–179 Boutin JA, Jockers R (2021) Melatonin controversies, an update. J Pineal Res 70(2):e12702 Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G et al (2006) Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41(4):313–323 Cully M (2022) A tale of two antiviral targets - and the COVID-19 drugs that bind them. Nat Rev Drug Discov 21(1):3–5 Ma X, Idle JR, Krausz KW, Gonzalez FJ (2005) Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 33(4):489–494 Liu X, Lu YF, Guan X, Zhao M, Wang J, Li F (2016) Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochem Pharmacol 109:70–82 Gross LZF, Sacerdoti M, Piiper A, Zeuzem S, Leroux AE, Biondi RM (2020) ACE2, the receptor that enables infection by SARS-CoV-2: biochemistry, structure, allostery and evaluation of the potential development of ACE2 modulators. ChemMedChem 15(18):1682–1690 Sekulic M, Harper H, Nezami BG, Shen DL, Sekulic SP, Koeth AT, Harding CV, Gilmore H, Sadri N (2020) Molecular detection of SARS-CoV-2 infection in FFPE samples and histopathologic findings in fatal SARS-CoV-2 cases. Am J Clin Pathol 154(2):190–200 Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N (2020) Comparison of Abbott ID now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol. https://doi.org/10.1128/JCM.00760-20 Keppler A, Gendreizig S, Gronemeyer T, Pick H, Vogel H, Johnsson K (2003) A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 21(1):86–89 Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612 Abraham MJ, Murtola T, Schulz R, Palla S, Smith JC, Hess B, Lindahl E (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2:19–25 Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubmuller H, MacKerell AD Jr (2017) CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods 14(1):71–73 Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I et al (2010) CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31(4):671–690